TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31141159
Drug: Oral glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glibenclamide (GBC)
Study: 23875809
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified doogh (DD; containing 150 mg calcium and 500 IU vitamin D/250 mL)
Study: 23875809
Drug: Calcium- and
Normalized name: Calcium- and magnesium-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium- and vitamin D-fortified doogh (CDD; containing 250 mg calcium and 500 IU vitamin D/250 mL)
Study: 23875809
Drug: Plain doogh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain doogh (PD; containing 150 mg calcium and no detectable vitamin D/250 mL)
Study: 19797554
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride) applied before in-office bleaching
Study: 19797554
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied before in-office bleaching
Study: 19797554
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride)
Study: 16895889
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (daily capsule containing 120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 µg Se, and 20 mg Zn)
Study: 11712091
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg primaquine daily for 20 weeks
Study: 8703810
Drug: Tucaresol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucaresol (oral doses; loading dose of 800 mg or 1200 mg for the first 4 days, followed by maintenance doses of 200 mg or 300 mg for the next 6 days; subsequent cohorts received 300 mg daily)
Study: 28253863
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg/h after a loading dose of 1.0 μg/kg for 10 min)
Study: 28253863
Drug: Propofol (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.6 μg/ml target effect site concentration)
Study: 26844873
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR (40 mg, n = 14)
Study: 24954822
Drug: Supportive Nondirective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Nondirective Therapy (SNDT)
Study: 15726912
Drug: Menotropins plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menotropins plus mini-dose GnRH-analog (600 microg/day) (group B)
Study: 15726912
Drug: Menotropins plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menotropins plus standard dose GnRH-analog (900 microg/day) (group C)
Study: 7631946
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR) alone
Study: 7631946
Drug: Glucose-free infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-free infusion (LR group)
Study: 7631946
Drug: 2% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% glucose in lactated Ringer's solution (D2LR) and 5% glucose in lactated Ringer's solution (D5LR)
Study: 7631946
Drug: Glucose-free solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-free solution (LR group)
Study: 28590244
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg administered as two 1‐mL subcutaneous injections every 2 weeks
Study: 28590244
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg administered as one 2‐mL injection delivered over different rates (10 seconds, 1 minute, 12 minutes)
Study: 28590244
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg administered by different injection rates
Study: 19432292
Drug: Drug acquisition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug acquisition
Study: 19432292
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment days
Study: 19432292
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drug sales
Study: 1812773
Drug: Antihistamines
Normalized name: ANTIHISTAMINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines
Study: 8191660
Drug: He‐Ne laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: He‐Ne laser treatment (wavelength 0.63 microns, light spot diameter 5 mm, energy 2 mWt, session duration 240 sec, 10 sessions)
Study: 3321890
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution with powdered rice and Dal moong
Study: 3321890
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO oral rehydration salt solution (ORS)
Study: 27012873
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g oral glucose
Study: 25912695
Drug: Apixaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks)
Study: 25912695
Drug: UFH/warfarin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH/warfarin (control treatment)
Study: 25717286
Drug: UFH/warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH/warfarin
Study: 25912695
Drug: Apixaban and
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban and UFH/warfarin
Study: 17998493
Drug: Trimethoprim-sulfamethoxazole, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole, 1 double-strength tablet twice daily for 3 days
Study: 17998493
Drug: Nitrofurantoin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin, 100 mg twice daily for 5 days
Study: 2508287
Drug: Transcutaneous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous nitroglycerin patches
Study: 21429719
Drug: n-3 long
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 long chain polyunsaturated fatty acids (3.7 g/d providing 1.7 g/d EPA and 1.2 g/d DHA)
Study: 21151623
Drug: Tramadol SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol SR 200 mg tablet (test product)
Study: 21151623
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (tramadol SR 200 mg tablet)
Study: 12411225
Drug: Atomoxetine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (once daily for 6 weeks)
Study: 12411225
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 6 weeks)
Study: 7898297
Drug: Neutrally-framed information
Normalized name: PCxx Neutral Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrally-framed information about chemotherapeutic treatment
Study: 7898297
Drug: Positively-framed information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positively-framed information about chemotherapeutic treatment
Study: 7898297
Drug: Negatively-framed information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negatively-framed information about chemotherapeutic treatment
Study: 212171
Drug: Prophylactic brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic brain irradiation (low doses)
Study: 24517948
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCA)
Study: 28810442
Drug: Internet‐administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet‐administered cognitive behavioral treatment
Study: 25106547
Drug: Thyme honey
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme honey nasal spray
Study: 19473635
Drug: Oral falecalcitriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral falecalcitriol
Study: 15209198
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush during vasectomy (10 mL normal saline)
Study: 12452382
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension inducing an urgency for defecation (average volume of air: 72.5 ml)
Study: 12452382
Drug: Control session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control session (20 ml of air in rectal balloon)
Study: 12452382
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension inducing an urgency for defecation
Study: 12452382
Drug: Both sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sessions (rectal distension and control)
Study: 9690724
Drug: Omeprazole (5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (5-day administration)
Study: 2732142
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (1 g dose, intravenous bolus) after 750 ml water (treatment A)
Study: 2732142
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (1 g dose, intravenous bolus) after 8 h of water restriction (treatment B)
Study: 2732142
Drug: Placebo under
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo under water restriction (treatment C)
Study: 27209586
Drug: CHF 5993
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 with cimetidine (800 mg twice daily for 6 days)
Study: 9028089
Drug: Amrinone (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (3-5 mg.kg-1.min-1) combined with dopamine (3-5 mg.kg-1.min-1)
Study: 9028089
Drug: Nitroglycerin (0.3-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.3-1.0 mg.kg-1.min-1) combined with dopamine (3-5 mg.kg-1.min-1)
Study: 8500234
Drug: Optimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal therapy in patients < 75 years old
Study: 2952156
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin phosphate 1%
Study: 6242074
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline
Study: 29110281
Drug: weight-loss intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: weight-loss intervention + 50,000 IU/week oral vitamin D3
Study: 24703512
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound therapy (SUST)
Study: 19865092
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin daily for 12 weeks
Study: 18262390
Drug: High-fat test
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat test meal (59 +/- 4 g fat; 71% of energy as fat) with high saturated:unsaturated fatty acids ratio (approximately 71:29)
Study: 18262390
Drug: High-fat test
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat test meal (59 +/- 4 g fat; 71% of energy as fat) with low saturated:unsaturated fatty acids ratio (approximately 55:45)
Study: 12663284
Drug: L-amino acid
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-amino acid diet supplying either 14 and 30 mg leucine x kg(‐1)x d(‐1) or 22 and 40 mg leucine x kg(‐1)x d(‐1)
Study: 12663284
Drug: [2H3]leucine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: [2H3]leucine administered orally at an intake of 40 mg x kg(‐1) x d(‐1)
Study: 10638903
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion at 5 microg x kg(‐1) x min(‐1) until the first response of each train‐of‐four had decreased by 70%.
Study: 10638903
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion at 20 microg x kg(‐1) x min(‐1) for 10 min.
Study: 6529613
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg xipamide
Study: 6529613
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg xipamide
Study: 6529613
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg xipamide
Study: 20337866
Drug: 16 mL
Normalized name: 16 ML Mvasi 25 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mL tea
Study: 20337866
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL tea
Study: 20337866
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL tea
Study: 17502874
Drug: Lean fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean fish (3 x 150 g portions of cod/week)
Study: 17502874
Drug: Fatty fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty fish (3 x 150 g portions of salmon/week)
Study: 18420395
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (DHA+EPA capsules, no seafood)
Study: 17502874
Drug: Control (sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sunflower oil capsules, no seafood)
Study: 12852722
Drug: Strict fasting
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict fasting capillary glucose target level (< 6.5 mmol/l)
Study: 12852722
Drug: Less strict
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less strict fasting capillary glucose target level (< 8.5 mmol/l)
Study: 19650825
Drug: AZD9343 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9343 320 mg
Study: 11966493
Drug: Baclofen 40
Normalized name: baclofen 40,000 MCG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 40 mg
Study: 17239705
Drug: Istaroxime at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime at doses >or=1 micro/kg per min
Study: 17239705
Drug: Istaroxime at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istaroxime at doses of 0.5 micro/kg per min
Study: 15150183
Drug: Piperacillin-tazobactam 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 3.375 g every 6 h
Study: 14642996
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at a mean dose of 2053 mg/day for a duration of 125 days
Study: 10442205
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol
Study: 7851201
Drug: Bran (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran (20 g/24 hr)
Study: 25257210
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy alone
Study: 15521899
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose salbutamol via pMDI + Volumatic
Study: 15521899
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose salbutamol via Diskus
Study: 11134196
Drug: Prednisone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (5 mg orally, four times a day)
Study: 11134196
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg orally, three times a day)
Study: 31760401
Drug: SLK triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLK triple therapy
Study: 28229548
Drug: Oligofructose (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (21 g for 12 weeks)
Study: 26681629
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (525 mg for days 1-3, 1050 mg for day 4)
Study: 19726379
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flurbiprofen axetil (group F)
Study: 19726379
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml intravenous saline (group C)
Study: 15152708
Drug: Chestnut Health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chestnut Health System's best‐practice Outpatient Treatment (CHS)
Study: 15152708
Drug: Cannabis Youth
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis Youth Treatment (CYT)
Study: 20664903
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg daily
Study: 12473255
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment in patients with pronounced ischaemia
Study: 9726529
Drug: Computer-assisted prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted prescription systems for anticoagulation management
Study: 8612436
Drug: Animal protein
Normalized name: Animal protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal protein diet (APD) (protein intake 1.1 g · kg‐1 · day‐1)
Study: 8612436
Drug: Vegetable protein
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable protein diet (VPD) (protein intake 0.95 g · kg‐1 · day‐1)
Study: 2094145
Drug: 3mg PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3mg PGE2 vaginal tablet
Study: 2094145
Drug: 1mg PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mg PGE2 vaginal gel
Study: 25845223
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus Lipitor (20 mg/tablet, one tablet per day for 6 weeks)
Study: 25845223
Drug: Lipitor (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipitor (20 mg/tablet, one tablet per day for 6 weeks)
Study: 22893038
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isoxsuprine tablets four times per day (Group A, n=15)
Study: 22893038
Drug: Dexamethasone with
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone with hyaluronidase intralesional injections (Group B, n=15)
Study: 22893038
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (Group C, n=10)
Study: 11641307
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion in group A (n=27)
Study: 11641307
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion in group B (n=18)
Study: 11641307
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion in group C (n=11)
Study: 9855336
Drug: Intravenous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous estradiol (various dosages)
Study: 27456983
Drug: Ongoing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing triple therapy
Study: 28754491
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 esterase inhibitor twice weekly (50 IU/kg; maximum 4200 IU)
Study: 28754491
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 esterase inhibitor once weekly (50 IU/kg; maximum 4200 IU)
Study: 22010226
Drug: Plastic grid
Normalized name: plastic IUD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plastic grid floor (G)
Study: 12111923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of handsearching and MEDLINE searching
Study: 10195518
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine (0.1 mL/kg) with 1:200,000 epinephrine (0.5 microg/kg)
Study: 9585275
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg followed by test dose
Study: 7644960
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy given by a physiotherapist
Study: 7644960
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care by a general practitioner (information and analgesics)
Study: 2664882
Drug: Carbamazepine as
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine as a comedication to haloperidol (24 mg haloperidol p.d.)
Study: 2664882
Drug: Haloperidol alone
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol alone (24 mg haloperidol p.d.)
Study: 559593
Drug: Chloramphenicol 50
Normalized name: chloramphenicol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 50 mg/kg body-weight
Study: 559593
Drug: Epicillin 1
Normalized name: ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epicillin 1 g six hourly
Study: 25161696
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng (200 mg twice daily for four weeks)
Study: 20495466
Drug: High-dose, extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, extended-release mesalamine
Study: 11796769
Drug: Outreach treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outreach treatment (mean of two sessions a week for 27.3 weeks)
Study: 9242847
Drug: Outreach treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outreach treatment
Study: 10518963
Drug: Trivastal 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivastal 50 mg LP (doses increased to 150-250 mg/day)
Study: 7486602
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of nimodipine (0, 30, 60 mg)
Study: 7486602
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of nimodipine (up to 150 mg in 12 hours)